You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恩華藥業(002262.SZ)擬斥2000萬元在上海設立全資子公司
格隆匯 03-27 18:41

格隆匯3月27日丨恩華藥業(002262.SZ)公佈,公司擬出資人民幣2000萬元在上海設立全資子公司,名稱暫定為“上海恩華醫藥有限公司(以登記註冊為準)”。

上海樞境生物科技有限公司(以登記註冊為準)經營範圍:生物科技,醫藥科技,醫療科技領域內的技術開發、技術諮詢、技術轉讓、技術服務,藥品研發、實驗室耗材的銷售、貨物進出口、技術進出口(以登記註冊為準)。

恩華藥業長期聚焦在中樞神經及麻醉、鎮痛領域的產品研發和銷售,立志成為國內精麻領域的龍頭企業,並建立一條在大中華區精麻領域最具競爭優勢的創新藥研發管線,創新藥研發將為公司可持續高質量發展提供保障。公司擬對外投資設立的上海樞境生物科技有限公司(以登記註冊為準),將主要從事生物科技,醫藥科技,醫療科技領域內的技術開發、技術諮詢、技術轉讓、技術服務,藥品研發、實驗室耗材的銷售、貨物進出口、技術進出口(以登記註冊為準)等業務。該子公司的成立將更有利於吸引海內外高端人才加入公司研發團隊,更有利於與優秀的高校和科研院所開展合作,更有利於提升公司研發管理水平和快速推出研發成果,也更有利於公司加快國際化的步伐。

此次在上海市浦東新區設立上海樞境生物科技有限公司(以登記註冊為準),可實現對公司現有研發業務的進一步拓展,在保持公司原有研發業務發展的情況下,該研發公司的設立將更有利於吸引海內外高端人才加入公司研發團隊,更有利於與優秀的高校和科研院所開展合作,更有利於提升公司研發管理水平和快速推出研發成果,也更有利於公司加快國際化的步伐,進一步增強了公司的核心競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account